



Financial Tearsheet

CORPORATE PROFILE

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with renal disease and their healthcare providers. In September 2014, the U.S. Food and Drug Administration approved Keryx's first medicine. Patients have been and continue to be at the center of our nearly 20-year corporate history.

Keryx established its corporate headquarters in Boston to support the U.S. launch of its first medicine. Joining Boston's pioneering biotech community has given us the opportunity to bring together a seasoned talent pool of innovative minds and resources that will allow us to continue toward our goal of building a leading renal company. We are a rapidly growing company, with approximately 200 employees across Boston and our field teams.

PRIMARY IR CONTACT

Lora Pike
Senior Director, Investor
Relations
Phone: 617-466-3511
E-mail: IR@keryx.com

STOCK PERFORMANCE

KERX (Common)

Exchange	NASDAQ (US Dollar)
Price	\$4.56
Change (%)	▼ 0.18 (3.80%)
Volume	1,166,823
52 Week Low	\$4.33
Market Cap	\$543,659,114
Rolling EPS	-1.50
PE Ratio	N/A
Shares Outstanding	119,223,490

Data as of 12/11/17 4:00 p.m. ET



RECENT HEADLINES & EVENTS

11/08/17 - 4:16 p.m.

[Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in November 2017](#)

11/07/17 - 7:03 a.m.

[U.S. FDA Approves Auryxia® \(ferric citrate\) Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis](#)

There are currently no events scheduled.

11/07/17 - 7:01 a.m.

**Keryx Biopharmaceuticals Announces Third Quarter 2017
Financial Results**

SEC FILINGS

Filing Date	Form
12/04/17	CT ORDER
12/04/17	CT ORDER
11/20/17	SC 13G/A
11/07/17	10-Q

CORPORATE GOVERNANCE

Ron Bentsur Chief Executive Officer

James Oliviero Chief Financial Officer

Powered By **EDGAR** Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed